FY2017 EPS Estimates for Alexion Pharmaceuticals, Inc. (ALXN) Boosted by Leerink Swann
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Equities researchers at Leerink Swann boosted their FY2017 earnings estimates for shares of Alexion Pharmaceuticals in a research report issued on Wednesday. Leerink Swann analyst now forecasts that the biopharmaceutical company will earn $5.17 per share for the year, up from their prior estimate of $5.09. Leerink Swann currently has a “Outperform” rating and a $182.00 target price on the stock.
Several other equities analysts also recently weighed in on the stock. Deutsche Bank AG reiterated a “buy” rating and issued a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $163.00 to $175.00 in a research note on Tuesday, September 5th. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 20th. Five analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $157.74.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/14/fy2017-eps-estimates-for-alexion-pharmaceuticals-inc-alxn-boosted-by-leerink-swann.html.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 146.46 on Thursday. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The company has a market cap of $32.69 billion, a P/E ratio of 63.51 and a beta of 1.40. The stock’s 50 day moving average is $137.59 and its 200-day moving average is $124.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the prior year, the business posted $1.13 EPS. The business’s revenue was up 21.1% compared to the same quarter last year.
In other news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,070 shares of company stock valued at $2,416,869. Company insiders own 4.35% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ALXN. Guardian Life Insurance Co. of America lifted its holdings in shares of Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Alexion Pharmaceuticals in the 1st quarter worth approximately $111,000. Fiduciary Trust Co. bought a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth approximately $111,000. Huntington National Bank lifted its holdings in shares of Alexion Pharmaceuticals by 1,084.6% in the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 987 shares during the last quarter. Finally, Penserra Capital Management LLC lifted its holdings in shares of Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 94.26% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.